National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine

Rapid Review

Commenced Completed Outcome
07/11/2012 19/11/2012 Full pharmacoeconomic assessment recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.